Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL993880 | 1.00 | CETP (0.78) | CETP | |
| SCHEMBL5955669 | 0.91 | CETP (0.77) | CETP | |
| SCHEMBL992971 | 0.91 | CETP (0.77) | CETP | |
| SCHEMBL6461793 | 0.90 | CETP (0.69) | CETP | |
| SCHEMBL993410 | 0.90 | CETP (0.69) | CETP | |
| SCHEMBL994836 | 0.88 | CETP (0.69) | CETP | |
| SCHEMBL6230115 | 0.88 | CETP (0.69) | CETP | |
| SCHEMBL992623 | 0.87 | CETP (1.00) | CETP | |
| SCHEMBL1436500 | 0.87 | CETP (1.00) | CETP | |
| SCHEMBL30211969 | 0.87 | CETP (1.00) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258352-B1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | BEND RES INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20060216351-A1 | Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers | PFIZER INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1114032-B1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2004-06-02 | — | — | EP | disclosed |
| US-6489478-B1 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INHIBITORS AND THE USE OF SUCH INHIBITORS TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN | PFIZER INC. | 2002-12-03 | — | — | US | disclosed |
| US-6140343-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS WHICH ARE USED TO ELEVATE HIGHDENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER LOW DENSITY LIPOPROTEIN-CHOLESTEROL AND TRIGLYCERIDES; FOR TREATING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, OBESITY | PFIZER (US) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216351-A1 | Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers | ABCB11, ABCG2, LIPA | CETP 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.